コンテンツへスキップ
Merck
  • Medication errors on oral chemotherapy in children with acute lymphoblastic leukemia in a developing country.

Medication errors on oral chemotherapy in children with acute lymphoblastic leukemia in a developing country.

Pediatric blood & cancer (2014-09-02)
Sapna Oberoi, Amita Trehan, Ram Kumar Marwaha
要旨

Medication errors occur universally. Inappropriate administration of chemotherapy drugs can have adverse effects in cancer patients. Our objective was to assess the rate and type of medication errors in children with acute lymphoblastic leukemia (ALL) receiving oral chemotherapy in outpatient setting. Prescription and administration of oral chemotherapy drugs in children with ALL were evaluated prospectively to determine rate and type of medication errors. Errors were defined as prescription (physician) level or administration (patient) level errors. Two hundred eighty-nine drugs were prescribed to 121 patients. Medication errors occurred in 36 (12.5%) prescriptions; 21(7.3%) were administration errors, 13 (4.5%) were prescribing errors, and two errors occurred at both levels. Mercaptopurine (6-MP) was significantly associated with higher rates of errors (Odds ratio [OR] = 2.1, 95% CI [confidence interval] 1-4.1) whereas lapses were less with dexamethasone (OR = 0.25, 95% CI 0.09-0.67). As a result of medication errors 28 (23.1%) patients received inappropriate doses. Twenty five (21%) patients received sub-optimal doses whereas three got higher doses of chemotherapy. On univariate analysis, socioeconomic status, education status of the caregiver, 6-MP and methotrexate were significantly associated with errors (P ≤ 0.05). On multivariate analysis, ≤ primary school education of the caregiver and prescription of methotrexate were independent predictors of errors. Medication errors affected nearly one fourth of the children receiving oral chemotherapy. Future studies are needed to look at effective interventions to avoid chemotherapy associated errors especially amongst the lower strata of society.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
デキサメタゾン, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone-Water Soluble, BioReagent, suitable for cell culture
Sigma-Aldrich
デキサメタゾン, ≥98% (HPLC), powder
SAFC
メトトレキサート
Sigma-Aldrich
メトトレキサート 水和物, ≥98% (HPLC), powder
Sigma-Aldrich
メトトレキサート 水和物, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
デキサメタゾン, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Supelco
デキサメタゾン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
メトトレキサート 溶液, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
6-メルカプトプリン 一水和物, 98%
Sigma-Aldrich
デキサメタゾン, meets USP testing specifications
Sigma-Aldrich
メトトレキサート 水和物, ≥99.0% (sum of enantiomers, HPLC)
Supelco
デキサメタゾン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
メトトレキサート, meets USP testing specifications
Supelco
メトトレキサート, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
デキサメタゾン, tested according to Ph. Eur.
メトトレキサート, European Pharmacopoeia (EP) Reference Standard
Supelco
デキサメタゾン, VETRANAL®, analytical standard
デキサメタゾン, European Pharmacopoeia (EP) Reference Standard
システム適合性用デキサメタゾン, European Pharmacopoeia (EP) Reference Standard
デキサメタゾン, European Pharmacopoeia (EP) Reference Standard
システム適合性用メトトレキサート, European Pharmacopoeia (EP) Reference Standard
メトトレキサート, European Pharmacopoeia (EP) Reference Standard